Akero Therapeutics Says That All Samples And Data Required For A Readout Of Topline Results From Phase 2b SYMMETRY Study Of Efruxifermin In NASH, Have Been Collected, Supporting The Expected Timing Of The Readout In October Of This Year
Portfolio Pulse from Benzinga Newsdesk
Akero Therapeutics has collected all samples and data required for a readout of topline results from its Phase 2b SYMMETRY study of Efruxifermin in NASH. The company expects to release the readout in October this year.
August 28, 2023 | 11:13 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Akero Therapeutics has completed data collection for its Phase 2b SYMMETRY study, with topline results expected in October. This could potentially impact the company's stock positively if the results are favorable.
The completion of data collection for the Phase 2b SYMMETRY study is a significant milestone for Akero Therapeutics. If the results, which are expected in October, are positive, this could potentially lead to a boost in the company's stock as it would indicate progress in their product development. However, if the results are not favorable, it could have a negative impact on the stock.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100